What recession? Pfizer (PFE stock) offers up healthy Q2 on covid drug outperformance


  • Pfizer stock loses ground despite earnings beat.
  • PFE reported an adjusted EPS of $2.04.
  • Covid drugs made up about 60% of its revenue, core company only grew 1%.

Not long after second-quarter US GDP numbers emerged on Thursday morning showing that the US economy is officially in a recession, Pfizer showed it hadn't noticed. The pharmaceutical giant offered up $2.04 in adjusted earnings per share (EPS) that blew past expectations by $0.26. In other words, Pfizer beat analyst consensus by nearly 15%. Revenue then came in at $27.7 billion, which was also well ahead of forecasts by $1.5 billion.

Also readAmazon Stock Deep Dive: AMZN price target at $106 with near-term risks offset by long-term growth

Pfizer stock is surprisingly down after blowing past its Q2 earnings expectations. Shares are off 4.1% to $49.44 in the first 20 minutes of Thursday's regular session. The Federal Reserve reported Q2 GDP that fell 0.9% YoY. Since this is the second consecutive quarter of decline, the US economy is officially in a recession.

Pfizer earnings and outlook: Vaccine provides shot in the arm

Pfizer's coronavirus vaccine Comirnaty and its covid treatment Paxlovid together brought in more than half of the revenue. Comirnaty had sales of $8.85 billion, and Paxlovid nearly matched it with $8.12 billion. This has been the most popular coronavirus vaccine in the world, and Centers for Disease Control estimate 355 million doses of the two-shot vacccine have been administered. For the full year, PFE now estimates it will have sales of $32 billion for Comirnaty and $22 billion for Paxlovid.

Unlike the first quarter, when it beat on adjusted EPS but missed on GAAP EPS, Pfizer reported GAAP EPS for Q2 of $1.73, which was ahead of consensus for $1.64.

The impact of the strong US dollar is very much having a negative impact on the impressive results. Pfizer issued guidance that the lower limit to full-year EPS was being raised by $0.24 and full-year revenue by $2 billion in constant currency terms. When currency fluctuations are taken into account (you know, like in the real world), Pfizer's guidance says full-year revenue will come in $3 billion below consensus and that EPS will only add $0.05 to the prior lower end of guidance (moving from $6.25 to $6.30). 

Besides the currency effect, a major drawback to the earnings was that when covid drugs are taken out of the mix, Pfizer's sales only grew about 1% YoY. Pfizer's JAK inhibitor drug saw sales fall 27% YoY, and its Chantix anti-smoking drug reduced shipments by 99%.

Pfizer stock forecast: Stuck in the middle of pattern

Pfizer stock has been trading inside a symmetrical triangle since February. The apex of the wedge is around $49, so PFE shares have been circling that price all year. To break out of the wedge, PFE stock must close on the weekly chart below above $52.62. The bottom trend line of the wedge structure is at $46.85 at the moment.

The Moving Average Convergence Divergence (MACD) is barely moving. Look for the MACD to wake up before there is any real movement. For now, it looks like Pfizer stock will search for support at the lower trend line near $47.

 

PFE weekly chart

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Recommended content


Recommended content

Editors’ Picks

AUD/USD recovers above 0.6750 after Australian jobs data

AUD/USD recovers above 0.6750 after Australian jobs data

AUD/USD picks up a late bid and recovers above 0.6750 in Asian trading on Thursday, following the release of mixed Australian employment data. The extended post-Fed US Dollar recovery, amid a cautious market mood, could limit the pair's upside ahead of US data. 

AUD/USD News
USD.JPY jumps toward 144.00 on the road to recovery

USD.JPY jumps toward 144.00 on the road to recovery

USD/JPY gains traction and approaches 144.00 in Thursday's Asian session. The uptick of the pair is bolstered by the impressive US Dollar recovery. Investors shift their attention to the US data and the Bank of Japan interest rate decision on Friday. 

USD/JPY News
Gold price remains on the defensive amid the post-FOMC USD recovery from YTD low

Gold price remains on the defensive amid the post-FOMC USD recovery from YTD low

Gold price struggles to lure buyers despite the Fed’s jumbo interest rate cut on Wednesday. A further recovery in the US bond yields underpins the USD and caps the non-yielding metal. Concerns about an economic slowdown, along with geopolitical risks, help limit the downside.

Gold News
Ethereum attempts recovery following first rate cut in four years

Ethereum attempts recovery following first rate cut in four years

Ethereum is trading above $2,330 on Wednesday as the market is recovering following the Federal Reserve's decision to cut interest rates by 50 basis points. Meanwhile, Ethereum exchange-traded funds recorded $15.1 million in outflows.

Read more
Australian Unemployment Rate expected to hold steady at 4.2% in August

Australian Unemployment Rate expected to hold steady at 4.2% in August

The Australian Bureau of Statistics will release the monthly employment report at 1:30 GMT on Thursday. The country is expected to have added 25K new positions in August, while the Unemployment Rate is foreseen to remain steady at 4.2%.

Read more
Moneta Markets review 2024: All you need to know

Moneta Markets review 2024: All you need to know

VERIFIED In this review, the FXStreet team provides an independent and thorough analysis based on direct testing and real experiences with Moneta Markets – an excellent broker for novice to intermediate forex traders who want to broaden their knowledge base.

Read More

Forex MAJORS

Cryptocurrencies

Signatures